Vai al contenuto principale della pagina

Applying Next Generation Sequencing and Transgenic Models to Rare Disease Research



(Visualizza in formato marc)    (Visualizza in BIBFRAME)

Autore: Gouw Arvin M Visualizza persona
Titolo: Applying Next Generation Sequencing and Transgenic Models to Rare Disease Research Visualizza cluster
Pubblicazione: Frontiers Media SA, 2020
Descrizione fisica: 1 online resource (119 p.)
Soggetto topico: Medical genetics
Science: general issues
Soggetto non controllato: genetic analysis
Genomics
Next generation sequencing
Rare disease
transgenic
Persona (resp. second.): JaishankarAmritha
BrooksGeorge A
GouwArvin M
Sommario/riassunto: A rare disease is a disease that occurs infrequently in the general population, typically affecting fewer than 200,000 Americans at any given time. More than 30 million people in the United States of America (USA) and 350 million people globally suffer from rare diseases. Out of the 7000+ known rare diseases, less than 5% have approved treatments. Rare diseases are frequently chronic, progressive, degenerative, and life-threatening, compromising the lives of patients by loss of autonomy. In the USA, it can take years for a rare disease patient to receive a correct diagnosis. The socioeconomic burden for rare disease is huge. For those living with diagnosed rare diseases, there is no support system or resource bank for navigating financial, educational, or other aspects of having a rare disease. The purpose of this Research Topic is to bring together leading researchers, non-profit organizations, healthcare providers/diagnostic companies, and pharma/biotech/CROs in the field to provide a broad perspective on the latest advances, challenges, and opportunities in rare disease research.
Titolo autorizzato: Applying Next Generation Sequencing and Transgenic Models to Rare Disease Research  Visualizza cluster
Formato: Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione: Inglese
Record Nr.: 9910557223103321
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui